Stine Aistrup Eriksen

Stine Aistrup Eriksen

Auto-generated profile, based on publicly available information

Stine Aistrup Eriksen

Univ Coll Northern Denmark, Dept Midwifery, Selma Lagerlofs Vej 2, DK-9220 Aalborg, Denmark

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2014 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
LHL. Hansen
L. Hansen
KPK. D. Petersen
K. D. Petersen
SES. A. Eriksen
S. A. Eriksen
BLB. L. Langdahl
B. L. Langdahl
PEP. A. Eiken
P. A. Eiken
PVP. Vestergaard
P. Vestergaard

31 December 2013 in Current Drug Safety
Verified
Journal Article
Open access
PDF file
JSJakob Starup-Linde
Jakob Starup-Linde
ØKØystein Karlstad
Øystein Karlstad
SEStine Aistrup Eriksen
Stine Aistrup Eriksen
PVPeter Vestergaard
Peter Vestergaard
HBHeleen K. Bronsveld
Heleen K. Bronsveld
MBMarie L De Bruin
Marie L De Bruin
Background: Patients suffering from diabetes mellitus (DM) may experience an increased risk of cancer; however, it is not certain whether this effect is due to diabetes per se. Objective: To examine the association between DM and cancers by a systematic review and meta-analysis according to the PRISMA guidelines. Data Sources: The systematic literature search includes Medline at PubMed, Embase, Cinahl, Bibliotek.dk, Cochrane library, Web of Science and SveMed+ with the search terms: “Diabetes mellitus”, “Neoplasms”, and “Risk of cancer”. Study Eligibility Criteria: The included studies compared the risk of cancer in diabetic patients versus non-diabetic patients. All types of observational study designs were included. Results: Diabetes patients were at a substantially increased risk of liver (RR=2.1), and pancreas (RR=2.2) cancer. Modestly elevated significant risks were also found for ovary (RR=1.2), breast (RR=1.1), cervix (RR=1.3), endometrial (RR=1.4), several digestive tract (RR=1.1-1.5), kidney (RR=1.4), and bladder cancer (RR=1.1). The findings were similar for men and women, and unrelated to study design. Meta-regression analyses showed limited effect modification of body mass index, and possible effect modification of age, gender, with some influence of study characteristics (population source, cancer- and diabetes ascertainment). Limitations: Publication bias seemed to be present. Only published data were used in the analyses. Conclusions: The systematic review and meta-analysis confirm the previous results of increased cancer risk in diabetes and extend this to additional cancer sites. Physicians in contact with patients with diabetes should be aware that diabetes patients are at an increased risk of cancer.

1 July 2016 in Molecular and Cellular Neuroscience
Verified
Journal Article
Closed access
JPJohan Palmfeldt
Johan Palmfeldt
KHKim Henningsen
Kim Henningsen
SEStine Aistrup Eriksen
Stine Aistrup Eriksen
HMHeidi K. Müller
Heidi K. Müller
OWOve Wiborg
Ove Wiborg

25 February 2015 in Arthritis
Verified
Journal Article
Open access
PDF file
HBHenning Bliddal
Henning Bliddal
SEStine A. Eriksen
Stine A. Eriksen
RCRobin Christensen
Robin Christensen
TLTove Lorenzen
Tove Lorenzen
MHMichael S. Hansen
Michael S. Hansen
PVPeter Vestergaard
Peter Vestergaard
Objectives. To study adherence to methotrexate (MTX) and factors of importance thereof in patients with rheumatoid arthritis (RA). Methods. Patients with a hospital diagnosis of RA (ICD10 codes M05.X or M06.X) after January 1, 1997, and aged ≥18 years at the date of first diagnosis/contact, with at least one prescription of MTX (L04AX03), were included. Results. A total of 18,703 (47.6%) patients had ever used MTX among 39,286 with a diagnosis of RA; among the MTX users, 16,503 (88.2%) had filed more than one MTX prescription. The median time from diagnosis to first MTX prescription was 0.66 (IQR 0.26–1.80) years. In those who filed more than one MTX prescription, the mean adherence time for ≥7.5 mg MTX per week was 1,925 (IQR 467–3,056) days for patients treated in private practice versus 1,892 (IQR 452–3,316) days for patients treated in hospital. The main determinants of nonadherence were female gender, younger age, and time from diagnosis to initiation of MTX. Conclusions. Treatment at hospital or in private practice did not influence the adherence to MTX. Nonmodifiable factors of importance were gender and age, while adherence to MTX therapy decreased with time lapse between diagnosis and prescription.

18 August 2024 in Midwifery
Verified
Journal Article
Closed access
JNJane Hyldgaard Nielsen
Jane Hyldgaard Nielsen
IJIngrid Jepsen
Ingrid Jepsen
SEStine Aistrup Eriksen
Stine Aistrup Eriksen
RMRikke Damkjær Maimburg
Rikke Damkjær Maimburg

1 May 2013 in Bone Abstracts
Verified
Journal Article
Closed access
JSJakob Starup-Linde
Jakob Starup-Linde
SEStine Aistrup Eriksen
Stine Aistrup Eriksen
PVPeter Vestergaard
Peter Vestergaard
Introduction: Diabetes mellitus may affect bone via bone structure, bone density, and biochemical markers of bone turnover. The aim of this meta-analysis was to examine biochemical markers of bone turnover in diabetics compared to non-diabetics. Methods: A systematic literature search was conducted using Pubmed, Embase, Cinahl, and Svemed+ with the search terms: ‘Diabetes mellitus’, ‘Diabetes mellitus type 1’, ‘Insulin dependent diabetes mellitus’, ‘Diabetes mellitus type 2’, ‘Non insulin dependent diabetes mellitus’, ‘Bone’, ‘Bone and Bones’, ‘Bone diseases’, ‘Bone turnover’, ‘Hemoglobin A Glycosylated and ‘HbA1c’. After removing duplicates from this search 1188 records were screened by title and abstract and 75 records were assessed by full text for inclusion. After screening, 22 records fulfilled the criteria for the meta-analysis. Revman was used in the data analysis. Results: From the pooled data in the meta-analysis the bone markers, osteocalcin (P<0.01), and CTX (P<0.01) were significantly lower among diabetics than non-diabetics, however, bone specific alkaline phosphatase (P=0.53), deoxypyridinoline (P=0.99), NTX (P=0.06) and C1CP (P=0.54) did not differ. Alkaline phosphatase (P<0.01) was increased in diabetics. I relation to calcitropic hormones; 25-hydroxy vitamin D was lower in diabetics (P=0.02), while PTH (P=0.56) and serum calcium (P=0.54) remained unchanged. All markers displayed very high heterogeneity by I2 statistics. No publication bias was present (analyses by funnel plot). Conclusion: A dissociative pattern of biochemical bone markers of formation and bone resorption was present in diabetics. We speculate that this could point to a measurement error caused by glycation of bone markers, which may alter the configuration of some of the markers thus disrupting the measurement of these.